nach oben

Erschienen in:

2022 | OriginalPaper | Buchkapitel

11. Idiopathische Lungenfibrose

verfasst von : Lars Hagmeyer, Nicolas Kahn, Anne Marie Kirsten, Martin Kolb

Erschienen in: Seltene Lungenerkrankungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die idiopathische Lungenfibrose ist eine chronisch progrediente fibrosierende interstitielle Pneumonie unbekannter Ursache, die primär beim älteren Erwachsenen auftritt und sich radiologisch sowie histologisch durch das Vorliegen eines UIP-Musters („Usual Interstitial Pneumonia“) auszeichnet. Die Prognose ist ungünstig, interindividuell ist der Verlauf jedoch sehr variabel. Die zentrale Säule der Diagnostik ist die hochauflösende Computertomografie, eine Histologiegewinnung ist nur selten erforderlich. Die Diagnosestellung sollte in einer interdisziplinären Fallevaluation erfolgen. Therapeutisch stellt die Lungentransplantation die einzige kurative Option dar. Mit den antifibrotisch wirksamen Substanzen Pirfenidon oder Nintedanib kann eine Progressionsverzögerung erreicht werden. Supportive Ansätze sollten früh in die Behandlung integriert werden.

Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S (1997) CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 168:79–83PubMedCrossRef

Allaix ME, Fisichella PM, Noth I et al (2014) Idiopathic pulmonary fibrosis and gastroesophageal reflux. Implications for treatment. J Gastrointest Surg 18:100–104. (discussion 4–5)PubMedCrossRef

Behr J, Günther A, Bonella F et al (2018) German guideline for idiopathic pulmonary fibrosis – update on pharmacological therapies 2017. Pneumologie 72:155–168PubMedCrossRef

Behr J, Günther A, Bonella F et al (2020) S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose. Pneumologie 74:263–293PubMedCrossRef

Bettencourt PE, Del Bono EA, Spiegelman D, Hertzmark E, Murphy RL Jr (1994) Clinical utility of chest auscultation in common pulmonary diseases. Am J Respir Crit Care Med 150:1291–1297PubMedCrossRef

du Bois RM, Weycker D, Albera C et al (2011a) Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 184:1382–1389PubMedCrossRef

du Bois RM, Weycker D, Albera C et al (2011b) Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184:459–466PubMedCrossRef

du Bois RM, Weycker D, Albera C et al (2011c) Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 183:1231–1237PubMedCrossRef

Borensztajn K, Crestani B, Kolb M (2013) Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers – insights from the bench side. Respiration 86:441–452PubMedCrossRef

Carloni A, Poletti V, Fermo L, Bellomo N, Chilosi M (2013) Heterogeneous distribution of mechanical stress in human lung: a mathematical approach to evaluate abnormal remodeling in IPF. J Theor Biol 332:136–140PubMedCrossRef

Collard HR, Anstrom KJ, Schwarz MI, Zisman DA (2007) Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131:897–899PubMedCrossRef

Collard HR, Ryerson CJ, Corte TJ et al (2016) Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 194:265–275PubMedCrossRef

Corte TJ, Wort SJ, Talbot S et al (2012) Elevated nocturnal desaturation index predicts mortality in interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 29:41–50PubMed

Cottin V, Nunes H, Brillet PY et al (2005) Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 26:586–593PubMedCrossRef

Culver DA, Behr J, Belperio JA et al (2019) Patient registries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 200:160–167PubMedPubMedCentralCrossRef

Daniels CE, Yi ES, Ryu JH (2008) Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 32:170–174PubMedCrossRef

Dowman LM, McDonald CF, Hill CJ et al (2017) The evidence of benefits of exercise training in interstitial lung disease: a randomized controlled trial. Thorax 72:610–619PubMedCrossRef

Hagmeyer L, Theegarten D, Treml M et al (2016) Validation of transbronchial cryobiopsy in interstitial lung disease – interim analysis of a prospective trial and critical review of the literature. Sarcoidosis Vasc Diffuse Lung Dis 33(1):2–9PubMed

Hagmeyer L, Theegarten D, Wohlschläger J et al (2019) Transbronchial cryobiopsy in fibrosing interstitial lung disease: modifications of the procedure lead to risk reduction. Thorax 74:711–714PubMedCrossRef

Hetzel J, Maldonado F, Ravaglia C et al (2018) Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. Respiration 95:188–200

Hoeper MM, Andreas S, Bastian A et al (2011) Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(1):45–53CrossRef

Hopkins RB, Burke N, Fell C et al (2016) Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J 48:187–195PubMedCrossRef

Huppmann P, Sczepanski B, Boensch M et al (2013) Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 42:444–453PubMedCrossRef

Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G (2014) Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370:2093–2101CrossRef

Jankowich MD, Rounds S (2010) Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung 188:365–373PubMedPubMedCentralCrossRef

Kato E, Takayanagi N, Takaku Y et al (2018) Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res 4:00111–02016PubMedPubMedCentralCrossRef

Khor YH, Ng Y, Barnes H et al (2020) Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev 29:190158PubMedCrossRef

Kim DS (2013) Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res 14:86PubMedPubMedCentralCrossRef

Kim WY, Mok Y, Kim GW et al (2015) Association between idiopathic pulmonary fibrosis and coronary artery disease: a case-control study and cohort analysis. Sarcoidosis Vasc Diffuse Lung Dis 31:289–296PubMed

Kimura M, Taniguchi H, Kondoh Y et al (2013) Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 85:456–463PubMedCrossRef

King TE Jr, Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–2092PubMedCrossRef

Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K (2010) Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 15:265–271PubMedCrossRef

Kolb M, Raghu G, Wells AU et al (2018) Nintedanib plus Sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med 379:1722–1731PubMedCrossRef

Kolilekas L, Manali E, Vlami KA et al (2013) Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med 9:593–601PubMedPubMedCentralCrossRef

Kreuter M, Ehlers-Tenenbaum S, Schaaf M et al (2015) Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis 31:266–274PubMed

Kreuter M, Bendstrup E, Russell AM et al (2017) Palliative care in interstitial lung disease: living well. Lancet Respir Med 5:968–980PubMedCrossRef

Kreuter M, Ochmann U, Koschel D et al (2018) DGP interstitial lung disease patient questionnaire. Pneumologie 72:446–457PubMedCrossRef

Kreuter M, Polke M, Walsh SLF et al (2020) Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonization. Eur Respir J 55:1901760PubMedCrossRef

Lancaster LH, Mason WR, Parnell JA et al (2009) Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 136:772–778PubMedPubMedCentralCrossRef

Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R (2007) The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 101:2534–2540PubMedCrossRef

Lee JS, Collard HR, Anstrom KJ et al (2013) Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 1:369–376PubMedPubMedCentralCrossRef

Ley B, Ryerson CJ, Vittinghoff E et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156:684–691PubMedCrossRef

Lynch DA, Sverzellati N, Travis WD et al (2018) Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 6:138–153PubMedCrossRef

Magnussen H, Kirsten AM, Kohler D et al (2008) Leitlinien zur Langzeit-Sauerstofftherapie. Pneumologie 62:748–756. (Deutsche Gesellschaft Fur Pneumologie und Beatmungsmedizin e. V.)PubMedCrossRef

Maldonado F, Danoff SK, Wells AU et al (2020) Transbronchial cryobiopsy for the diagnosis of interstitial lung diseases: CHEST guideline and expert panel report. Chest 157:1030–1042

Mallick S (2008) Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med 102:1355–1359PubMedCrossRef

Martinez FJ, Safrin S, Weycker D et al (2005) The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142:963–967PubMedCrossRef

Mejia M, Carrillo G, Rojas-Serrano J et al (2009) Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 136:10–15PubMedCrossRef

Mermigkis C, Stagaki E, Tryfon S et al (2010) How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? Sleep Breath 14:387–390PubMedCrossRef

Mermigkis C, Bouloukaki I, Antoniou KM et al (2013) CPAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: does it offer a better quality of life and sleep? Sleep Breath 17:1137–1143PubMedCrossRef

Moor CC, Mostard RLM, Grutters JC et al (2020) Home monitoring in patients with idiopathic pulmonary fibrosis. A rabdomized controlled trial. Am J Respir Crit Care Med 202:393–401PubMedCrossRef

Nathan SD, Basavaraj A, Reichner C et al (2010) Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 104:1035–1041PubMedCrossRef

Nathan SD, Behr J, Collard HR et al (2019) Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomized, placebo-controlled phase 2 b study. Lancet Respir Med 7:780–790PubMedCrossRef

Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:1760–1769PubMedCrossRef

Orens JB, Estenne M, Arcasoy S et al (2006) International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25:745–755PubMedCrossRef

Ozawa Y, Suda T, Naito T et al (2009) Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 14:723–728PubMedCrossRef

Panos RJ, Mortenson RL, Niccoli SA, King TE Jr (1990) Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88:396–404PubMedCrossRef

Park J, Kim DS, Shim TS et al (2001) Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17:1216–1219PubMedCrossRef

Park JH, Kim DK, Kim DS et al (2007) Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia. Eur J Cardiothorac Surg 31:1115–1119PubMedCrossRef

Perez-Bogerd S, Wuyts W, Barbier V et al (2018) Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomized controlled trial. Respir Res 19:182PubMedPubMedCentralCrossRef

Raghu G, Freudenberger TD, Yang S et al (2006) High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 27:136–142PubMedCrossRef

Raghu G, Rochwerg B, Zhang Y et al (2015) An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192:e3–e19PubMedCrossRef

Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44–e68PubMedCrossRef

Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087PubMedCrossRef

Russel AM, Adamali H, Molyneaux PL et al (2016) Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 194:989–997CrossRef

Ryerson CJ, Arean PA, Berkeley J et al (2012) Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology 17:525–532PubMedCrossRef

Ryerson CJ, Hartman T, Elicker BM et al (2013) Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 144:234–240PubMedCrossRef

Shimbori C, Gauldie J, Kolb M (2013) Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Curr Opin Pulm Med 19:446–452PubMedCrossRef

Smith JS, Gorbett D, Mueller J, Perez R, Daniels CJ (2013) Pulmonary hypertension and idiopathic pulmonary fibrosis: a dastardly duo. Am J Med Sci 346:221–225PubMedCrossRef

Smits JM, Nossent GD, de Vries E et al (2011) Evaluation of the lung allocation score in highly urgent and urgent lung transplant candidates in Eurotransplant. J Heart Lung Transplant 30:22–28PubMedCrossRef

Song JW, Hong SB, Lim CM, Koh Y, Kim DS (2011) Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37:356–363PubMedCrossRef

Sugino K, Ishida F, Kikuchi N et al (2014) Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone. Respirology 19:239–245PubMedCrossRef

Troy LK, Grainge C, Corte TJ et al (2020) Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med 8:171–181PubMedCrossRef

Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B (2014) Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349:209–220PubMedCrossRef

Yanagihara T, Sato S, Upagupta C et al (2019) What have we learned from basic science studies on idiopathic pulmonary fibrosis? Eur Respir Rev 28:190029PubMedCrossRef

Yang IV, Coldren CD, Leach SM et al (2013) Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 68:1114–1121PubMedCrossRef

Titel: Idiopathische Lungenfibrose
verfasst von: Lars Hagmeyer
Nicolas Kahn
Anne Marie Kirsten
Martin Kolb
Verlag: Springer Berlin Heidelberg
Buch: Seltene Lungenerkrankungen
Print ISBN: 978-3-662-63650-3

Electronic ISBN: 978-3-662-63651-0

Copyright-Jahr: 2022
DOI: https://doi.org/10.1007/978-3-662-63651-0_11

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

11. Idiopathische Lungenfibrose

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin